Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005762 · ClinicalTrials.gov registry record · NA

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
90
Enrollment target
8
Study locations

NCT00005762: Completed NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00005762 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005762, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
90 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir \[NFV\], indinavir \[IDV\], ritonavir soft gel capsules \[RTV sgc\], or saquinavir soft gel capsules \[SQV sgc\]). Anti-HIV therapy with 3 or 4 drugs is currently the recommended approach for treating HIV infections. Doctors need to know the best dosages of certain drugs when they are given in combination. This study will measure the blood levels of APV alone, APV combined with EFV, and APV/EFV plus a second PI in healthy volunteers. It will study the safety and tolerance of these drugs.

Conditions Studied

HIV Infections

Interventions

  • DRUG Ritonavir
  • DRUG Efavirenz
  • DRUG Indinavir sulfate
  • DRUG Nelfinavir mesylate
  • DRUG Amprenavir

Study Locations (8)

California

  • Stanford CRS - Palo Alto

Colorado

  • University of Colorado Hospital CRS - Aurora

Hawaii

  • Univ. of Hawaii at Manoa, Leahi Hosp. - Honolulu

Indiana

  • Indiana Univ. School of Medicine, Infectious Disease Research Clinic - Indianapolis

Maryland

  • Johns Hopkins Adult AIDS CRS - Baltimore

Ohio

  • The Ohio State University Medical Center - Columbus

Tennessee

  • Vanderbilt Univ. Med. Ctr., AIDS Clinical Trials Ctr. - Nashville

Washington

  • University of Washington AIDS CRS - Seattle

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2001-03
Est. Completion 2004-05
Phase NA
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00005762 record still lists

NCT00005762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Ritonavir is the first listed.

NCT00005762 lists 8 locations in 8 states (California, Colorado, Hawaii).

Frequently Asked Questions

What is clinical trial NCT00005762 about?

NCT00005762 is a clinical study titled "Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers". The purpose of this study is to measure the blood levels of amprenavir (APV) alone, APV combined with efavirenz (EFV), and APV/EFV combined with a third drug (nelfinavir \[NFV\], indinavir \[IDV\], ritonavir soft gel capsules \[RTV sgc\], or saquinavir soft gel capsules \[SQV sgc\]). Anti-HIV thera...

What is the current status of trial NCT00005762?

This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2001-03. Estimated completion is 2004-05.

What conditions does trial NCT00005762 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00005762?

The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG), Amprenavir (DRUG).

Who is sponsoring clinical trial NCT00005762?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00005762 being conducted?

This trial has 8 study locations across California, Colorado, Hawaii, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00005762's enrollment target sits among peer trials

90 287th of 542 higher than 251 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00005762, the US trial registry maintained by the National Library of Medicine. NCT00005762 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.